Education
About Us
Working with TipRanks
Follow Us
Zenas BioPharma, Inc. (ZBIO)
NASDAQ:ZBIO
ZBIO Stock Chart & Stats
$22.48
-$0.05(-0.51%)
At close: 4:00 PM EST
$22.48
-$0.05(-0.51%)
Day’s Range― - ―
52-Week Range$6.11 - $44.60
Previous CloseN/A
Volume96.53K
Average Volume (3M)1.07M
Market Cap
$1.17B
Enterprise Value$815.82M
Total Cash (Recent Filing)$290.88M
Total Debt (Recent Filing)$798.00K
Price to Earnings (P/E)―
Beta0.36
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.90
Shares Outstanding53,679,165
10 Day Avg. Volume694,313
30 Day Avg. Volume1,074,154
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.10
Price to Sales (P/S)68.44
P/FCF Ratio-2.86
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue54.39
Enterprise Value/Gross Profit-24.70
Enterprise Value/Ebitda-4.16
Forecast
1Y Price Target
$41.20Price Target Upside83.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-4.45
Revenue Forecast (FY)$36.26M
Bulls Say, Bears Say
Bulls Say
At‑home Subcutaneous Dosing AdvantageObexelimab's at‑home subcutaneous dosing, ability to pause treatment for vaccinations or procedures, and favorable safety profile support patient preference and could accelerate commercial adoption versus infusions.
Pipeline Diversification And BTK ProgramDevelopment of a Bruton’s tyrosine kinase inhibitor with differentiated CNS exposure and a pivotal trial design offers an additional commercialization pathway that could materially expand company value beyond the IgG4‑RD asset.
Regulatory Approval ProspectsAnalyst increased the probability of approval after a positive Phase 3 readout, viewing obexelimab as likely to gain regulatory clearance in major markets and lift the stock on approval expectations.
Bears Say
Addressable Market LimitationsTargeting moderate and milder IgG4‑RD cases while severe multi‑organ patients remain reliant on established infusions limits the total addressable market and constrains revenue potential.
Comparative Efficacy Versus CompetitorAlthough the Phase 3 met its primary endpoint, the results were perceived as less robust than a competing cytolytic infusion, which may weaken competitive positioning and reduce pricing power.
Lowered Expectations And Valuation PressureAnalyst reductions to expected market penetration and pricing led to a rating adjustment and valuation cut, which could exacerbate investor pessimism and pressure the share price.
Zenas BioPharma, Inc. News
ZBIO FAQ
What was Zenas BioPharma, Inc.’s price range in the past 12 months?
Zenas BioPharma, Inc. lowest stock price was $6.11 and its highest was $44.60 in the past 12 months.
What is Zenas BioPharma, Inc.’s market cap?
Zenas BioPharma, Inc.’s market cap is $1.17B.
When is Zenas BioPharma, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Zenas BioPharma, Inc.’s earnings last quarter?
Zenas BioPharma, Inc. released its earnings results on Aug 12, 2025. The company reported -$1.25 earnings per share for the quarter, missing the consensus estimate of -$1.038 by -$0.212.
Is Zenas BioPharma, Inc. overvalued?
According to Wall Street analysts Zenas BioPharma, Inc.’s price is currently Undervalued.
Does Zenas BioPharma, Inc. pay dividends?
Zenas BioPharma, Inc. does not currently pay dividends.
What is Zenas BioPharma, Inc.’s EPS estimate?
Zenas BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zenas BioPharma, Inc. have?
Zenas BioPharma, Inc. has 53,679,165 shares outstanding.
What happened to Zenas BioPharma, Inc.’s price movement after its last earnings report?
Zenas BioPharma, Inc. reported an EPS of -$1.25 in its last earnings report, missing expectations of -$1.038. Following the earnings report the stock price went up 1.705%.
Which hedge fund is a major shareholder of Zenas BioPharma, Inc.?
Currently, no hedge funds are holding shares in ZBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zenas BioPharma, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.20 (83.27% Upside)
$41.20 (83.27% Upside)
Blogger Sentiment
Bullish
ZBIO Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 12.3%
Last 30 Days ▲ 12.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
191.56%
12-Months-Change
Fundamentals
Return on Equity
-68.33%
Trailing 12-Months
Asset Growth
-20.18%
Trailing 12-Months
Company Description
Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
ZBIO Stock 12 Month Forecast
Average Price Target
$41.20
▲(83.27% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---